Governments have decided they will pay any price in the fight against COVID-19 while the pharmaceutical sector is already grappling with supply. Nobody should expect the PBS in 2021, 2022 or beyond to look like it does in 2020 - and that is before you even consider the long-term budgetary impact of the shock about to hit the economy.
This is just the start of a challenge that will almost certainly leave a permanent 'scar'
March 21, 2020 Latest NewsComment
Latest Video
New Stories
-
Moderna announces positive Phase 3 result for influenza vaccine
July 1, 2025 - - Latest News -
Research lagging for sarcoma, despite accounting for one third of adolescent cancer deaths
July 1, 2025 - - Latest News -
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 - - Latest News -
The real question is why expectations were so high in the first place
July 1, 2025 - - Latest News -
National Pharmacies appoints experienced industry leader as new CEO
July 1, 2025 - - Latest News -
Tetratherix lists on the ASX following successful IPO
June 30, 2025 - - Australian Biotech -
LTR Pharma achieves key FDA milestone through extractables study
June 30, 2025 - - Australian Biotech